Biogen: Q2 earnings down 5%, but target EPS raised
(CercleFinance.com) - Biogen has reported a 5% decline in adjusted net income to 1.
65 billion dollars for Q2 2020, or 10.26 dollars per share, with revenues up 2% at 3.68 billion dollars.
Alongside the release of its quarterly results, Biogen has announced an increase in its FY 2020 adjusted EPS target to between 34 dollars and 36 dollars, compared to a previous target range of between 31.5-33.5 dollars.
However, the pharmaceutical company is more cautious about its sales, now forecasting approximately 13.8-14.2 billion dollars, against a previous target range of 14-14.3 billion dollars.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
65 billion dollars for Q2 2020, or 10.26 dollars per share, with revenues up 2% at 3.68 billion dollars.
Alongside the release of its quarterly results, Biogen has announced an increase in its FY 2020 adjusted EPS target to between 34 dollars and 36 dollars, compared to a previous target range of between 31.5-33.5 dollars.
However, the pharmaceutical company is more cautious about its sales, now forecasting approximately 13.8-14.2 billion dollars, against a previous target range of 14-14.3 billion dollars.
Copyright (c) 2020 CercleFinance.com. All rights reserved.